To the Editor Komai et al. (1) described the first case of isoniazid (INH)-induced rhabdomyolysis in Japan; they speculated that mitochondrial dysfunction and adenosine triphosphate (ATP) depletion were causes of rhabdomyolysis, citing studies that suggested that INH and its metabolite hydrazine induce dysfunction of mitochondrial complexes I and II and ATP depletion (2) . Two major metabolic pathways of INH are known. The main metabolic pathway of INH is through acetylation by N-acetyltransferases 2 (NAT2) followed by hydrolyzation by amidase to acetylhydrazine. The other is an alternative pathway in which INH is converted to the toxic metabolite hydrazine by amidase. Hydrazine and acetylhydrazine are further metabolized by cytochrome P450 2E1 to toxic reactants that get detoxified by glutathione-S-transferase (3). However, no studies have measured hydrazine or acetylhydrazine in patients with rhabdomyolysis. We determined the INH-induced rhabdomyolysis pathophysiology by measuring these metabolites continuously in a patient with a NAT2 polymorphism and rhabdomyolysis due to INH overdose.
An otherwise healthy 13-year-old girl was prescribed INH 200 mg/day and pyridoxal phosphate hydrate 20 mg/day for latent tuberculosis. However, she attempted suicide by taking an overdose of INH (6,400 mg, 112 mg/kg). She developed status epilepticus lasting for 90 min and was admitted to our hospital. 
